Literature DB >> 27092462

Adiponectin induces CXCL1 secretion from cancer cells and promotes tumor angiogenesis by inducing stromal fibroblast senescence.

Lun Cai1, Shengyuan Xu1, Chunmei Piao1, Shulan Qiu1, Huihua Li2, Jie Du3.   

Abstract

Adiponectin is an adipocyte-specific adipocytokine with proliferative and pro-angiogenic effects that regulates many biological processes, including immunity, insulin resistance, and inflammation. The oncogenic role of adiponectin has been implicated in several cancer types. Stromal cells within tumor contribute tumor growth and angiogenesis; however, it is not clear that how adiponectin regulates stromal cell-mediated tumorigenesis. In this study, using the tumor xenograft models, we demonstrated that tumor development was severely impaired in mouse subcutaneous cancer tissue and metastasis tumor tissue in adiponectin knockout mice. Our results indicated adiponectin deficiency resulted in decrease of blood vessel and stromal senescent fibroblasts in subcutaneous and metastasis tumor tissue. These observations were confirmed in vitro, in which co-cultured tumor cells and fibroblasts treated with adiponectin promoted ECs tube formation. A secretion of CXCL1 by adiponectin-treated tumor cells was observed during the process of inducing stromal fibroblast senescence. Furthermore, stromal cells senescence was through p53 and p16 pathways. Taken together, our results indicate that adiponectin promotes stromal cell senescence within invasive colon cancer contributing to angiogenesis and tumor growth in part through the production of CXCL1 and may serve as a therapeutic target for tumor patients.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  CXCL1; adiponectin; senescence; stromal cells; tumor angiogenesis

Mesh:

Substances:

Year:  2015        PMID: 27092462     DOI: 10.1002/mc.22428

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  9 in total

Review 1.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

Review 2.  Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.

Authors:  Lokman Varisli; Osman Cen; Spiros Vlahopoulos
Journal:  Immunology       Date:  2019-12-22       Impact factor: 7.397

Review 3.  The bifurcated role of adiponectin in colorectal cancer.

Authors:  Debrup Chakraborty; Wei Jin; Jing Wang
Journal:  Life Sci       Date:  2021-04-19       Impact factor: 6.780

4.  Adiponectin promotes human jaw bone marrow mesenchymal stem cell chemotaxis via CXCL1 and CXCL8.

Authors:  Yinfei Pu; Mengke Wang; Yingying Hong; Yuwei Wu; Zhihui Tang
Journal:  J Cell Mol Med       Date:  2017-02-08       Impact factor: 5.310

5.  Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.

Authors:  Yen-Yun Wang; Huan-Da Chen; Steven Lo; Yuk-Kwan Chen; Yu-Ci Huang; Stephen Chu-Sung Hu; Ya-Ching Hsieh; Amos C Hung; Ming-Feng Hou; Shyng-Shiou F Yuan
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

Review 6.  The Importance of CXCL1 in Physiology and Noncancerous Diseases of Bone, Bone Marrow, Muscle and the Nervous System.

Authors:  Jan Korbecki; Magdalena Gąssowska-Dobrowolska; Jerzy Wójcik; Iwona Szatkowska; Katarzyna Barczak; Mikołaj Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

7.  Expression and Prognostic Role of CXCL1 Gene in Colorectal Adenocarcinoma.

Authors:  Chao Xia; Lifeng He; Yi Sun
Journal:  Comput Intell Neurosci       Date:  2022-08-02

Review 8.  Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis.

Authors:  Lucilla Crudele; Elena Piccinin; Antonio Moschetta
Journal:  Nutrients       Date:  2021-06-19       Impact factor: 5.717

9.  Adiponectin and adiponectin receptor 1 overexpression enhance inflammatory bowel disease.

Authors:  Yu-Ju Peng; Tang-Long Shen; Yu-Shan Chen; Harry John Mersmann; Bing-Hsien Liu; Shih-Torng Ding
Journal:  J Biomed Sci       Date:  2018-03-14       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.